Abstract 2402P
Background
Bladder cancer is the most prevalent form of urothelial carcinoma. There is an urgent need for timely and accurate identification of molecular alterations to guide tailored therapeutic treatment. Urinary tumor DNA (utDNA) analysis not only holds promise as a valuable tool in bladder cancer diagnosis and monitoring, but also has the potential to identify actionable mutations that can be targeted with personalized therapies.
Methods
This prospective study enrolled 154 patients with bladder cancer in real-world settings, comprising 65 patients with non-muscle invasive bladder cancer (NMIBC) and 89 patients with muscle invasive bladder cancer (MIBC). The cohort included treatment-naive patients as well as those who had received treatment and were at risk of recurrence. Urine samples were collected from each patient. PredicineCARE, a NGS liquid biopsy assay, was applied to detect somatic alterations in urinary tumor DNA (utDNA).
Results
The study detected a total of 368 somatic mutations and 14 copy number variants in 65 NMIBC patients, and 485 somatic mutations and 43 copy number variants in 89 MIBC patients. Among NMIBC patients, the most frequently mutated genes were TP53 (38%), TERT (37%), ARID1A (22%), and BRCA2 (20%). Among MIBC patients, the most frequently mutated genes were TP53 (57%), TERT (39%), ERBB2 (24%), ARID1A (20%), and PIK3CA (20%). The prevalence of FGFR2/3 variations was 15% in NMIBC and 13% in MIBC among all patients, while 38.5% of NMIBC patients and 26.3% of MIBC patients who were confirmed to be treatment-naïve harbored FGFR2/3 variations. The prevalence of ERBB2 and TP53 mutations was significantly higher in MIBC than in NMIBC (ERBB2: 21/89 vs. 4/65, p<0.01; TP53: 51/89 vs. 25/65, p<0.05). Conversely, the prevalence of RARA was significantly higher in NMIBC than in MIBC (5/65 vs. 0/89, p<0.05).
Conclusions
The present study unveils a comprehensive mutational landscape of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) utilizing urine samples from real-world patients. These results demonstrate the promising potential of urine-based next-generation sequencing (NGS) assays to identify tumor-derived variants for clinical diagnosis and targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2401P - Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
Presenter: Ruiyun Zhang
Session: Poster session 24
2403P - CDKN2A deletions are a mechanism for p16 inactivation in urothelial bladder carcinomas and are associated with an aggressive tumor phenotype
Presenter: Martina Kluth
Session: Poster session 24
2404P - Concordance of genomic alterations by next-generation sequencing in tumor tissue versus urinary tumor DNA and circulating tumor DNA in bladder cancer
Presenter: Song Xue
Session: Poster session 24
2405P - Prognostic significance of circulating tumor DNA in patients with urothelial carcinoma: A systematic review and meta-analysis
Presenter: Liu Haoyang
Session: Poster session 24
2407TiP - SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
Presenter: Andrea Necchi
Session: Poster session 24
2408TiP - DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints
Presenter: Francesca Jackson-Spence
Session: Poster session 24
2409TiP - A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
Presenter: Shilpa Gupta
Session: Poster session 24